Fractyl Health, Inc. (GUTS) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Fractyl Health, Inc. is a clinical-stage metabolic therapeutics company developing the Revita (duodenal mucosal resurfacing system) and Rejuva (pancreatic gene therapy) platforms to treat obesity and type 2 diabetes. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | YTD 2026 (6 Months) | Balance Sheet (June 30, 2026) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(25,538) | $(16,320) | N/A |
| Operating Expenses | $(19,096) | $(39,916) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $47,140 |
| Total Debt (Notes Payable) | N/A | N/A | $30,446 |
| Warrant Liabilities | N/A | N/A | $11,839 |
| Stockholders' Equity (Deficit) | N/A | N/A | $(1,665) |
Note: The company reported no revenue for the period. Net loss for the six months ended June 30, 2026, was significantly lower than the prior year due to a non-cash gain on warrant liabilities.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by 26.8% in Q2 2026 compared to Q2 2025 ($19.1M vs. $26.1M). This reduction was driven by a 34.7% decrease in R&D expenses ($13.8M vs. $21.2M) due to reduced clinical spending on Revita and Rejuva programs.
- Net Loss: Net loss improved to $(25.5M) in Q2 2026 from $(27.9M) in Q2 2025. For the six-month period, net loss improved significantly to $(16.3M) from $(51.6M) in the prior year.
- Other Income/Expense: The six-month period included a $24.6 million non-cash gain from the change in fair value of warrant liabilities, which offset operating losses. In Q2 2026 specifically, there was a $5.5 million loss on warrant liabilities.
- Liquidity: Cash and cash equivalents decreased from $81.5 million at year-end 2025 to $47.1 million at June 30, 2026, reflecting a net cash burn of $38.4 million from operating activities over the six-month period.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year from the issuance date. Cash resources ($47.1M) are projected to fund operations only into early 2027. The company plans to mitigate this through financing, regulatory approvals, and cost-cutting.
- Clinical Milestones:
- Revita: Topline six-month data from the REMAIN-1 Pivotal Cohort is anticipated in early Q4 2026. A potential De Novo marketing application submission is targeted for late Q4 2026.
- Rejuva: First-in-human dosing of RJVA-001 is expected in H2 2026, with preliminary data anticipated in the same period.
- Nasdaq Compliance: The company received notice on March 13, 2026, of non-compliance with the $1.00 minimum bid price requirement. It has until September 9, 2026, to regain compliance or face potential delisting.
- Financing: The At-The-Market (ATM) offering was terminated effective April 6, 2026. The company must secure additional capital to fund operations beyond early 2027.
Investor Verification Checklist
- Cash Runway: Verify the timeline for securing additional financing given the "substantial doubt" going concern warning and cash balance of $47.1M.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement by September 9, 2026, to avoid delisting.
- Debt Covenants: Confirm continued compliance with the 2023 Notes liquidity covenant (minimum $10M cash balance) and the upcoming principal payment schedule starting September 30, 2027.
- Clinical Data: Await the Q4 2026 topline data for the Revita REMAIN-1 Pivotal Cohort, which is critical for the anticipated De Novo submission.
- Warrant Liability Volatility: Note that net income/loss is heavily influenced by non-cash fair value adjustments of warrant liabilities, which fluctuate with stock price.